FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 52 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR The right combination for early detection August 4, 2021 Phytochemicals and Antioxidants December 11, 2020 New on NCI’s Websites for March 2025 March 13, 2025 FDA Approval Likely to Change Initial Treatment for Some People with... May 2, 2025 Load more HOT NEWS Sex, intimacy and cancer – That Cancer Conversation Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 Eight Factors May Link Disparities in Cancer Death Rates and Income Stopping neuropathy: One of chemotherapy’s most challenging side effects
